RxDoctor Payments Data

Michael Viksjo, MD

Gastroenterology · Union, NJNPI 1508028770

Payments from drug & device makers

$4,094in general payments, 2019–2025

Across 271 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$773
  • Takeda Pharmaceuticals U.S.A., Inc.$500
  • Pfizer$367
  • Bristol Myers Squibb$292
  • Ardelyx, Inc.$270
  • Madrigal Pharmaceuticals$235
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,06699%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,094 in reported general payments places this provider in the 60th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$58,766
Medicare patients
181
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab14$95,362
LinzessLinaclotide37$38,182
XifaxanRifaximin13$29,007
ZenpepLipase/Protease/Amylase14$28,245
Dexlansoprazole DrDexlansoprazole41$9,515
Mesalamine22$7,725
ClenpiqSod Picosulf/Mag Ox/Citric Ac37$6,457
Omeprazole398$5,816
Mesalamine ErMesalamine13$1,210
Pantoprazole Sodium129$1,032
Esomeprazole Magnesium24$857
Famotidine50$799
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$393
Ondansetron OdtOndansetron16$293
Dicyclomine Hcl17$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$773$38,18237 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$210$29,00713 claims
Aimmune Therapeutics, Inc.Zenpep$92$28,24514 claims
Ferring Pharmaceuticals Inc.Clenpiq$100$6,45737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →